Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04671251|
Recruitment Status : Completed
First Posted : December 17, 2020
Last Update Posted : May 4, 2022
- Study Details
- Tabular View
- Results Submitted
- How to Read a Study Record
This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma.
The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: AEVI-007||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Sequential Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, Open-Label, Dose-Escalation Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma|
|Actual Study Start Date :||December 15, 2020|
|Actual Primary Completion Date :||March 30, 2022|
|Actual Study Completion Date :||March 30, 2022|
50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.
- Recommended Phase 2 Dose [ Time Frame: Cohorts 1-3 will take approximately 4-5 months ]Identify the recommended Phase 2 dose based on safety, pharmacokinetics and pharmacodynamics observed in this Phase 1b study.
- Incidence of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Approximately 9 months ]
- Incidence of Clinically Significant Changes in Clinical Laboratory Results [ Time Frame: Approximately 9 months ]
- Incidence of Clinically Significant Changes in Vital Signs [ Time Frame: Approximately 9 months ]
- Incidence of Clinically Significant Changes in Electrocardiogram Recordings [ Time Frame: Approximately 9 months ]
- Incidence of Clinically Significant Changes to Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score [ Time Frame: Approximately 9 months ]
- Incidence of Clinically Significant Changes in Physical Examination Findings [ Time Frame: Approximately 9 months ]
- Maximum Observed Concentration of AEVI-007 [ Time Frame: Approximately 9 months ]
- Apparent Terminal Half-Life of AEVI-007 [ Time Frame: Approximately 9 months ]
- Clearance of AEVI-007 [ Time Frame: Approximately 9 months ]
- Volume of Distribution of AEVI-007 [ Time Frame: Approximately 9 months ]
- Area Under the Concentration-Time Curve From Time 0 to Time t of AEVI-007 [ Time Frame: Approximately 9 months ]
- Anti-myeloma activity [ Time Frame: Approximately 9 months ]To assess the anti-myeloma activity of AEVI-007 based on International Myeloma Working Group (IMWG) criteria for response
- Determination of ADAs [ Time Frame: Approximately 9 months ]To determine the incidence of anti-drug antibodies to AEVI-007.
- Time to Response (TTR) [ Time Frame: Approximately 9 months ]Defined as the time from start of the treatment to the first observation of PR or better. TTR is restricted to only subjects with confirmed responses.
- Progression Free Survival (PFS) [ Time Frame: Approximately 9 months ]Defined as the duration from start of the treatment to disease progression or death (regardless of cause of death), whichever comes first
- Duration of Response [ Time Frame: Approximately 9 months ]Defined as the duration from the first observation of PR to the time of disease progression, with deaths from causes other than progression censored
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Subject has active R/R multiple myeloma.
Subject has measurable myeloma based on any of the following:
- Serum M-protein > 0.5 g/dL
- Urine M-protein > 200 mg/24 hours
- Serum free light chains > 10 mg/dL
- Measurable plasmacytoma or extramedullary disease
Subject has active myeloma despite prior therapy with a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.
Note: Subject must not be a candidate for regimens known to provide clinical benefit.
- Subject has an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
- Subject is > 18 years of age.
Subject has adequate hematopoietic, renal and hepatic function, defined as:
- Absolute neutrophil count > 1,000/μL; platelet count > 75,000/μL in patients with < 50% marrow involvement
- Absolute neutrophil count > 750/μL; platelet count > 50,000/μL in patients with >50% marrow involvement
- Serum creatinine < 2.5 mg/dL or calculated creatinine clearance of > 30 mL/min according to the Cockcroft-Gault equation
- Aspartate transaminase/alanine transaminase ≤2.5× the upper limit of normal (ULN) and total bilirubin < 2× the ULN
- If applicable, the subject has undergone prior autologous hematopoietic stem cell transplantation more than 100 days prior to the Screening Visit.
- Female patients of childbearing potential who are heterosexually active and male patients with female sexual partners of childbearing potential must agree to use an effective method of contraception (eg, oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device) or abstain from sexual activity during the study and for 220 days (5 half-lives) following the last dose of study medication, or to abstain from sexual intercourse for this duration of study participation. A woman not of childbearing potential is one who has undergone bilateral oophorectomies or who is post-menopausal, defined as the absence of menstrual periods for 12 consecutive months.
- Subject has provided written informed consent for this study.
- Subject has currently active infection requiring use of systemic antimicrobial therapy.
- Subject has received corticosteroids (>10 mg/daily prednisone or equivalent) or chemotherapy within 2 weeks of study drugs (4 weeks for nitrosourea, melphalan or monoclonal antibodies).
- Subject has hyperviscosity syndrome.
- Subject has central nervous system involvement by myeloma, including leptomeningeal involvement.
- Subject is judged to be at risk for impending fracture.
- Subject has known amyloidosis or POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes) syndrome.
- Subject had another malignancy within 1 year of study entry with high probability of recurrence.
- Subject is pregnant or lactating.
- Subject has a history of, or tests positive for, hepatitis B, untreated hepatitis C or human immunodeficiency virus (HIV). Subject with hepatitis C who has received a full course of anti-viral therapy or who is currently receiving anti-viral therapy with undetectable levels of hepatitis C RNA is eligible for the trial.
- Subject has undergone major surgery or trauma within 4 weeks of study entry.
- Subject has been previously treated with an anti IL 18 antibody.
- Subject is currently taking immunomodulatory drugs, including pharmacologic doses of systemic glucocorticoids (> 10 mg prednisone daily or equivalent), anti tumor necrosis factor alpha (TNFα) antibodies, anti-IL-17 antibodies, anti IL 12/23 antibodies, phosphodiesterase-4 (PDE-4) inhibitors, janus kinase (JAK) inhibitors, IL-6 inhibitors, rituximab, methotrexate, cyclosporine, mycophenolate.
- Subject with known active autoimmune disorders including, but not limited to, rheumatoid arthritis, lupus, systemic sclerosis, Sjogren's syndrome, psoriatic arthritis, ulcerative colitis, Crohn's disease, vasculitis, multiple sclerosis. Subjects with autoimmune endocrinopathies on stable doses of replacement hormone therapy are eligible for the trial.
- Subject has had a prior allogeneic transplant.
- Subject has New York Heart Association (NYHA) Class III or IV Congestive Heart Failure (CHF), myocardial infarction or acute coronary syndrome within 6 months prior to the Screening Visit, ongoing angina pectoris, severe peripheral vascular disease, or any other concomitant medical disorder that might interfere with the subject's participation in the trial or interpretation of the study data.
- Subject has psychiatric, substance abuse or social conditions that would interfere with the subject's participation or cooperation with the requirements of the trial.
- Subject has known hypersensitivity to any of the components of AEVI-007.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04671251
|United States, California|
|University of California, Davis Comprehensive Cancer Center|
|Sacramento, California, United States, 95817|
|James R. Berenson, MD., Inc.|
|West Hollywood, California, United States, 90069|
|United States, Florida|
|Florida Cancer Specialists|
|Lake Mary, Florida, United States, 32746|
|Florida Cancer Specialists|
|Sarasota, Florida, United States, 34232|
|United States, Maryland|
|American Oncology Partners of Maryland, PA|
|Bethesda, Maryland, United States, 20817|
|United States, North Carolina|
|Levine Cancer Institute|
|Charlotte, North Carolina, United States, 28204|
|United States, Wisconsin|
|Froedtert Hospital & the Medical College of Wisconsin|
|Milwaukee, Wisconsin, United States, 53226|
|Responsible Party:||Avalo Therapeutics, Inc.|
|Other Study ID Numbers:||
|First Posted:||December 17, 2020 Key Record Dates|
|Last Update Posted:||May 4, 2022|
|Last Verified:||January 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Blood Protein Disorders
Immune System Diseases